The economic impact of rapid Candida species identification by T2Candida among high-risk patients.

Abstract

INTRODUCTION:

This study estimates the cost-effectiveness and hospital budget impact of rapid candidemia identification using T2Candida, a novel diagnostic panel with same-day species-specific results.

MATERIALS & METHODS:

A 1-year decision-tree model estimates hospital costs (2013 US$) and effects (candidemia-related deaths) for faster diagnostics versus blood culture (BC), accounting for disease prevalence, distribution of Candida species, test characteristics (sensitivity/specificity/time to result), antifungal medication and differential length-of-stay and mortality by appropriate treatment timing.

RESULTS:

The model estimates a hospital with 5100 annual high-risk patients could possibly save $5,858,448 with T2Candida versus BC, a 47.6% decrease in candidemia diagnosis and treatment budget ($1149/patient tested), while averting 60.6% of candidemia-related mortality.

CONCLUSION:

Hospitals may observe lower candidemia-related inpatient costs and mortality with rapid Candida diagnosis.

• Authors: Sara Pinar Bilir, Cheryl P Ferrufino, Michael A Pfaller, Julie Munakata
• Journal: Future microbiology (Future Microbiol) Vol. 10 Issue 7 Pg. 1133-44 ( 2015) ISSN: 1746-0921 [Electronic] England
• PMID: 25848692 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Reagent Kits, Diagnostic

Topics

• Candida (classification, isolation & purification)
• Candidemia (diagnosis, drug therapy, economics, mortality)
• Cost-Benefit Analysis
• Decision Trees
• Female
• Hospital Costs
• Humans
• Male
• Microbial Sensitivity Tests
• Mycological Typing Techniques (economics)
• Reagent Kits, Diagnostic (economics)
• Risk